Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated by PET Imaging in Patients with Early Symptomatic Alzheimer's Disease

Next Previous
Trial Profile

Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated by PET Imaging in Patients with Early Symptomatic Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foralumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 20 Jan 2025 Planned initiation date changed from 1 Sep 2024 to 1 Apr 2025.
  • 17 Dec 2024 According to a Tiziana Life Sciences media release, first patient has been dosed with intranasal foralumab at Brigham and Women's Hospital in Boston, Massachusetts following on from their baseline PET scan.
  • 24 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top